ClinicalTrials.govcontrolled
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
ClinicalTrials.gov study NCT04209205. IPD Sharing: YES. Countries: 15. Publications: 0.
ShareScore
32/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 16
- Harmonization
- 8
- Access
- 4
- Reuse readiness
- 0
- Engagement
- 4